Cash, T., Marachelian, A., DuBois, S. G., Chi, Y., Baregamyan, A., Groshen, S. G., Jonus, H. C., Shamirian, A., Crowley, M., Goodarzian, F., Acharya, P. T., Pawel, B., Erbe, A. K., Shahi, A., Zaborek, J., Kennedy, E., Asgharzadeh, S., Villablanca, J. G., Pinto, N., Weiss, B. D., Mossé, Y. P., Desai, A. V., Macy, M. E., Granger, M., Vo, K. T., Sondel, P. M., Matthay, K. K., Park, J. R., Goldsmith, K. C. (2025). Phase I Study of 131 I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02612